Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0KMHHU
ADC Name	TRS-005
Synonyms	TRS 005; TRS005 Click to Show/Hide
Organization	Zhejiang Teruisi Pharmaceutical Inc.
Drug Status	Phase 1
Indication	In total 1 Indication(s) Non Hodgkin lymphoma [ICD11:2B33] Phase 1
Drug-to-Antibody Ratio	4.2
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	B-lymphocyte antigen CD20 (MS4A1)		Antigen Info
Payload Name	Undisclosed
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT05395533	Phase 1	A multicenter, single-arm, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics and effectiveness of TRS005 in patients with relapsed or refractory CD20-positive B-NHL.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	42.20% (all) 52.90% (DLBCL) 26.30% (FL) 60.00% (MCL) 66.70% (MZL) 0.00% (SLL/CLL) 42.90% (0.50 mg/kg) 33.30% (1.00 mg/kg) 43.80% (1.50 mg/kg) 50.00% (1.80 mg/kg)
Patients Enrolled	CD20-positive B-cell non Hodgkin lymphoma (NHL) and had failed 2 prior lines of standard treatment.
Administration Dosage	Seven dose cohorts (0.10, 0.50, 1.00, 1.50, 1.80, 2.10, 2.30 mg/kg iv d1,q21d).
*Related Clinical Trial*
NCT Number	NCT05395533	Clinical Status	Phase 1
Clinical Description	A multicenter, single-arm, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics and effectiveness of TRS005 in patients with relapsed or refractory CD20-positive B-NHL.

References

Ref 1	Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). J Clin Oncol. 2016 34:15_suppl, 4532-4532.